Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10102782 | 0.84 | KMT2A (0.39) | KMT2ASMN1; SMN2ALDH1A1MEN1LMNA | |
| SCHEMBL11982518 | 0.81 | KMT2A (0.50) | KMT2ASMN1; SMN2ALDH1A1MEN1LMNA | |
| SCHEMBL10102747 | 0.81 | ALDH1A1 (0.36) | KMT2ASMN1; SMN2ALDH1A1MEN1LMNA | |
| SCHEMBL10102752 | 0.79 | KMT2A (0.33) | KMT2ASMN1; SMN2ALDH1A1MEN1LMNA | |
| SCHEMBL10102749 | 0.78 | KMT2A (0.40) | KMT2ASMN1; SMN2ALDH1A1MEN1LMNA | |
| SCHEMBL12824763 | 0.78 | KMT2A (0.40) | KMT2ASMN1; SMN2ALDH1A1MEN1LMNA | |
| SCHEMBL11862134 | 0.77 | KMT2A (0.42) | KMT2ASMN1; SMN2ALDH1A1MEN1LMNA | |
| SCHEMBL10102775 | 0.76 | KMT2A (0.37) | KMT2ASMN1; SMN2ALDH1A1MEN1LMNA | |
| SCHEMBL11867402 | 0.72 | MAPT (0.43) | KMT2ASMN1; SMN2ALDH1A1MEN1LMNA | |
| SCHEMBL11870246 | 0.70 | KMT2A (0.36) | KMT2ASMN1; SMN2ALDH1A1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | KMT2A 1235/4885SMN1; SMN2 4190/4885ALDH1A1 3257/4885 |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | KMT2A 1810/4885SMN1; SMN2 4140/4885ALDH1A1 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.